Sugi Predict

Sugi Predict / Compounds / SCHEMBL794531

SCHEMBL794531

SCHEMBL794531

COC(=O)c1nc(N)sc1C

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.55
▸ KDM4E B2RXH2 5/20 0.55
▸ SMN1; SMN2 Q16637 2/20 0.55
▸ HSD17B10 Q99714 2/20 0.55
▸ HPGD P15428 2/20 0.55
▸ PKM P14618 3/20 0.53
▸ L3MBTL1 Q9Y468 1/20 0.53
▸ NPSR1 Q6W5P4 1/20 0.50
▸ RCE1 Q9Y256 1/20 0.49
▸ CYP1A2 P05177 1/20 0.49
▸ NOS1 P29475 1/20 0.43
▸ MAPT P10636 2/20 0.42
▸ GAA P10253 2/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ TSHR P16473 1/20 0.39
▸ KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL289441 0.81 ALDH1A1 (0.73) ALDH1A1KDM4ESMN1; SMN2HSD17B10HPGD
SCHEMBL8071199 0.81 ALDH1A1 (0.55) ALDH1A1KDM4ESMN1; SMN2HSD17B10HPGD
Bromide SCHEMBL16637333 0.80 ALDH1A1 (0.71) ALDH1A1KDM4ESMN1; SMN2HSD17B10HPGD
SCHEMBL16417686 0.80 NPSR1 (0.54) ALDH1A1KDM4ESMN1; SMN2HSD17B10HPGD
SCHEMBL23412984 0.79 KDM4E (0.55) ALDH1A1KDM4ESMN1; SMN2HSD17B10HPGD
SCHEMBL2476214 0.79 ALDH1A1 (0.54) ALDH1A1KDM4ESMN1; SMN2HSD17B10HPGD
SCHEMBL1549089 0.79 ALDH1A1 (0.54) ALDH1A1KDM4ESMN1; SMN2HSD17B10HPGD
SCHEMBL3046694 0.79 KDM4E (0.59) ALDH1A1KDM4ESMN1; SMN2HSD17B10HPGD
SCHEMBL1199384 0.78 NPSR1 (0.52) ALDH1A1KDM4ESMN1; SMN2HSD17B10HPGD
SCHEMBL23906182 0.78 NPSR1 (0.52) ALDH1A1KDM4ESMN1; SMN2HSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120006267-A Lead-free medium phosphorus chemical nickel plating solution 珠海联鼎化工设备有限公司 2025-05-16 — — CN claimed
EP-4745117-A1 NOVEL INDENONE DERIVATIVE AND USE THEREOF Amyloid Solution Inc. (KR) 2026-05-20 — — EP disclosed
EP-4570313-A2 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2025-06-18 — — EP disclosed
CN-120006267-A Lead-free medium phosphorus chemical nickel plating solution 珠海联鼎化工设备有限公司 2025-05-16 — — CN disclosed
US-20250002497-A1 IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION BRISTOL MYERS SQUIBB CO (US) 2025-01-02 — — US disclosed
CN-108383858-B Derivatives of imidazothiadiazoles and imidazopyrazines for the treatment of platelet aggregation 百时美施贵宝公司 2024-09-20 — — CN disclosed
US-12084452-B2 Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation BRISTOL-MYERS SQUIBB COMPANY (US) 2024-09-10 — — US disclosed
US-20230242535-A1 IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION BRISTOL MYERS SQUIBB CO (US) 2023-08-03 — — US disclosed
EP-4219477-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2023-08-02 — — EP disclosed
WO-2023141262-A1 BAX ACTIVATORS AND USE THEREOF IPSEN PHARMA S.A.S. (FR) 2023-07-27 — — WO disclosed
CN-1080720-C Thiazole derivatives HOFFMANN LA ROCHE (CH) 2002-03-13 — — CN disclosed
US-6344562-B1 ANTITUMOR AGENTS HOFFMANN-LA ROCHE INC. 2002-02-05 — — US disclosed
US-20020010316-A1 Thiazole derivatives ALIG LEO (CH) 2002-01-24 — — US disclosed
US-6320054-B1 INHIBIT BINDING OF ADHESIVE PROTEINS TO THE SURFACE OF DIFFERENT TYPES F CELL AND ACCORDINGLY INFLUENCE CELL-CELL AND CELL-MATRIX INTERACTIONS. HOFFMAN-LA ROCHE INC. 2001-11-20 — — US disclosed
WO-2001044226-A1 SERINE PROTEASE INHIBITORS TULARIK LIMITED (GB) 2001-06-21 — — WO disclosed
CN-1057091-C Novelc arbapenem derivatives MEIJI SEIKA CO (JP) 2000-10-04 — — CN disclosed
US-6100282-A Thiazole derivatives HOFFMAN-LA ROCHE INC. (US) 2000-08-08 — — US disclosed
CN-1224718-A Thiazole derivatives HOFFMANN LA ROCHE (CH) 1999-08-04 — — CN disclosed
EP-0928790-A1 Thiazole derivatives F. HOFFMANN-LA ROCHE AG (CH) 1999-07-14 — — EP disclosed
CN-1148390-A Novelc arbapenem derivatives MEIJI SEIKA CO (JP) 1997-04-23 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010316-A1 Thiazole derivatives VCAM1, SOST, TGFB1 ALDH1A1 1400/4885KDM4E 4278/4885SMN1; SMN2 3186/4885
US-20230242535-A1 IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION F2RL3, F2R, TMPRSS4 ALDH1A1 2611/4885KDM4E 3172/4885SMN1; SMN2 4341/4885
US-12084452-B2 Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation F2RL3, F2R, TMPRSS4 ALDH1A1 2611/4885KDM4E 3172/4885SMN1; SMN2 4341/4885
US-20250002497-A1 IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION F2RL3, F2R, TMPRSS4 ALDH1A1 2524/4885KDM4E 3131/4885SMN1; SMN2 4336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.